Interview with Steve Kerridge, Executive Chairman, Apodi
You joined Apodi in 2008, after a hiatus from the industry following the sale of your previous company, In2Focus, in 2007. What has been the most challenging aspect of your…
Address: One St Peters Road, Maidenhead, Berkshire SL6 7QU, United Kingdom
Tel: 01628 500890
Established in 2008 by a group of highly experienced outsourcing business specialists, Apodi provides comprehensive outsourcing solutions to the pharmaceutical and healthcare businesses and organisations.
Apodi recognizes that the business environment for these industry sectors is changing, and that there is a need for highly professional, tailored outsourcing services offering a rapid, effective response and delivering the best ROI.
Through commercial insight, market intelligence and highly motivated people, Apodi exists to help clients achieve improved outcomes and performance.
HR Services
Resourcing Services
Healthcare Services
Teams Services
Commercialization Services
You joined Apodi in 2008, after a hiatus from the industry following the sale of your previous company, In2Focus, in 2007. What has been the most challenging aspect of your…
Throughout his long career, John-Arne Rottingen has gathered experience across multiple domains from discovery research to public health and diplomacy that led him to become the founding CEO of the…
A roundup of some of the biggest stories coming out of the UK pharma industry, including AstraZeneca’s bid for cancer specialist Fusion Pharmaceuticals; the shutdown of Sanofi’s R&D site in…
Last year the UK-based pharma industry warned against the country’s waning competitiveness, condemning the government’s statutory scheme designed to control drug prices. UK-headquartered AstraZeneca joined the battle cry, claiming it…
The recent FDA decision to investigate the serious risk of patients developing new cancers after treatment with CAR-T therapies may have created some bad press around cell and gene therapies,…
A roundup of the biggest stories from UK pharma, including the latest agreement between the British government and industry on a renewed drug pricing clawback scheme; GSK’s search for deals…
AstraZeneca has made a bold move by offering its in-house digital clinical trial expertise to clinical research organisations (CROs) and other pharmaceutical companies via the launch of healthtech business Evinova.…
Since its creation over 20 years ago, the National Institute for Health and Care Excellence (NICE), the Health Technology Assessment (HTA) body for England and Wales, has forged a solid…
Could the UK’s re-joining of Horizon Europe, the EU’s EUR 95 billion research funding programme, be the latest sign that the country is ready to win back its global scientific…
The latest news from UK healthcare and life sciences, including the safety review of Novo Nordisk’s GLP-1 receptor agonists; VaxEquity’s grant to scale up RNA vaccine manufacturing; AstraZeneca/Quell Therapeutics cell…
Life sciences have been steadily losing ground in the UK with a significant drop in global R&D investments and a decreasing number of patients enrolled in clinical trials. The British…
Several macro-trends affected the pharmaceutical industry in 2022, impacting its inventory position, writes Matthew Bardell, managing director of specialist inventory consultants nVentic. Bardell highlights findings in a recent report –…
The latest news from UK healthcare and the life sciences, including a record rise in the number of people using private healthcare services due to significant strains on the National…
See our Cookie Privacy Policy Here
